Clearside Biomedical Inc 's (CLSD) Outlook - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 
Clearside Biomedical Inc   (NASDAQ: CLSD)
 



  Clearside Biomedical Inc Outlook

On March 12 2024 the Clearside Biomedical Inc provided following guidance

Clearside Biomedical Inc. reported its financial results for the fourth quarter and full year of 2023, along with a corporate update. The company announced that its Phase 2b ODYSSEY Wet AMD trial is progressing as planned, with topline data anticipated to be released in the third quarter of 2024. This trial is a significant milestone for Clearside Biomedical as it evaluates the efficacy of its innovative treatment for wet age-related macular degeneration. The company is optimistic about the results of the trial and remains committed to advancing its research and development efforts in the ophthalmology field. Clearside Biomedical continues to focus on delivering novel therapies to patients in need and is dedicated to improving outcomes for individuals with sight-threatening conditions.





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.